NASDAQ:MREOMereo BioPharma Group Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mereo BioPharma Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.74 -0.16 (-5.52 %) (As of 08/6/2020 04:00 PM ET) Add Compare Share Today's Range$2.74Now: $2.74▼$2.9350-Day Range$2.72MA: $3.02▼$3.4052-Week Range$0.69Now: $2.74▼$4.27Volume313,637 shsAverage Volume214,288 shsMarket Capitalization$68.23 millionP/E RatioN/ADividend YieldN/ABeta1.89 ProfileAnalyst RatingsAdvanced ChartCompetitorsInstitutional OwnershipHeadlinesSocial Media Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; MPH-966, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease. The company also develops OMP-305B83 and OMP-313M32, which are anti-cancer therapeutic candidates in clinical development stage. Mereo BioPharma Group plc was founded in 2015 and is headquartered in London, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Mereo BioPharma Group. Previous Next 2.4 Community Rank Outperform VotesMereo BioPharma Group has received 11 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMereo BioPharma Group has received 12 “underperform” votes. (Add your “underperform” vote.)Community SentimentMereo BioPharma Group has received 52.17% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Mereo BioPharma Group and other stocks. Vote “Outperform” if you believe MREO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MREO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMereo BioPharma Group does not currently pay a dividend.Dividend GrowthMereo BioPharma Group does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mereo BioPharma Group insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 13.18% of the stock of Mereo BioPharma Group is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mereo BioPharma Group are expected to decrease in the coming year, from ($1.21) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mereo BioPharma Group is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mereo BioPharma Group is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMereo BioPharma Group has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.48 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MREO Previous Symbol CUSIPN/A CIKN/A Webwww.mereobiopharma.com Phone44-33-3023-7300Debt Debt-to-Equity Ratio0.36 Current Ratio1.02 Quick Ratio1.02Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.06 per share Price / Book1.33Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees37 Outstanding Shares24,900,000Market Cap$68.23 million Next Earnings Date9/15/2020 (Estimated) OptionableNot Optionable $2.74 -0.16 (-5.52 %) (As of 08/6/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MREO News and Ratings via Email Sign-up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter. Mereo BioPharma Group (NASDAQ:MREO) Frequently Asked Questions How has Mereo BioPharma Group's stock been impacted by COVID-19 (Coronavirus)? Mereo BioPharma Group's stock was trading at $1.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MREO stock has increased by 76.8% and is now trading at $2.74. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Mereo BioPharma Group? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mereo BioPharma Group in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mereo BioPharma Group. When is Mereo BioPharma Group's next earnings date? Mereo BioPharma Group is scheduled to release its next quarterly earnings announcement on Tuesday, September 15th 2020. View our earnings forecast for Mereo BioPharma Group. Has Mereo BioPharma Group been receiving favorable news coverage? Press coverage about MREO stock has been trending positive on Friday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Mereo BioPharma Group earned a daily sentiment score of 2.1 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Mereo BioPharma Group. Who are some of Mereo BioPharma Group's key competitors? Some companies that are related to Mereo BioPharma Group include MEI Pharma (MEIP), Concert Pharmaceuticals (CNCE), Trevena (TRVN), Menlo Therapeutics (MNLO), Magenta Therapeutics (MGTA), Osmotica Pharmaceuticals (OSMT), Immunic (IMUX), Ritter Pharmaceuticals (RTTR), REDHILL BIOPHAR/S (RDHL), NextCure (NXTC), Spero Therapeutics (SPRO), ProQR Therapeutics (PRQR), Urovant Sciences (UROV), Lannett (LCI) and Northwest Biotherapeutics (NWBO). View all competitors. What other stocks do shareholders of Mereo BioPharma Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mereo BioPharma Group investors own include Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), Nabriva Therapeutics (NBRV), OpGen (OPGN), Provention Bio (PRVB), VBI Vaccines (VBIV), Vaxart (VXRT), Aduro BioTech (ADRO), ImmunoGen (IMGN) and Arcus Biosciences (RCUS). Who are Mereo BioPharma Group's key executives? Mereo BioPharma Group's management team includes the following people: Dr. Denise Scots-Knight, Co-Founder, CEO & Exec. Director (Age 60)Mr. Charles Sermon, Co-Founder, Gen. Counsel & Company Sec. (Age 50)Dr. Alastair MacKinnon, Co-Founder & Chief Medical Officer (Age 49)Mr. John Richard, Co-Founder & Head of Corp. Devel. (Age 62)Mr. Richard Crispin Morgan Jones, CFO & Exec. Director (Age 53) When did Mereo BioPharma Group IPO? (MREO) raised $49 million in an initial public offering on the week of April 23rd 2018. The company issued 2,800,000 shares at a price of $17.62 per share. Cowen, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Cantor Fitzgerald Europe were co-managers. What is Mereo BioPharma Group's stock symbol? Mereo BioPharma Group trades on the NASDAQ under the ticker symbol "MREO." How do I buy shares of Mereo BioPharma Group? Shares of MREO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Mereo BioPharma Group's stock price today? One share of MREO stock can currently be purchased for approximately $2.74. How big of a company is Mereo BioPharma Group? Mereo BioPharma Group has a market capitalization of $68.23 million. The company earns $-44,490,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Mereo BioPharma Group employs 37 workers across the globe. What is Mereo BioPharma Group's official website? The official website for Mereo BioPharma Group is www.mereobiopharma.com. How can I contact Mereo BioPharma Group? Mereo BioPharma Group's mailing address is ONE CAVENDISH PLACE FOURTH FLOOR, LONDON X0, W1G0QF. The company can be reached via phone at 44-33-3023-7300. This page was last updated on 8/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
